Cancer Patient Experience Survey
Each year more than 70,000 patients in England take part in a Cancer Patient Experience Survey (CPES). The survey is run by Quality Health on behalf of NHS England. Established in 2010, this annual survey measures the experience of cancer patients across a number of aspects during their care pathway. These include emotional aspects (such as how sensitively a person was told that they had cancer) as well practical issues (for example the length of time a person had to wait before first seeing a hospital doctor).
2015 has seen changes to the survey – we recommend you read this guide alongside the results.
League table of hospital trusts
Based on the results of the CPES, Macmillan has previously created a league table of the best and worst performing trusts in England.
2014 findings show that patients treated by London NHS services report a worse experience of care compared with patients treated elsewhere in England. To see the top and bottom 10 hospitals in the league table, download the 2014 league table and insight briefing [PDF].
To read more about why patients in London reported worse experiences, download the paper What explains worse patient experience in London?.
We have also funded important research into the validity of the survey, looking at the effect of case mix (ie the mix of patients treated in a hospital) on survey scores, to ensuring that comparisons made between hospitals are fair.
Inequality in reported cancer patient experience by socio-demographic characteristic and cancer site
Researchers from the University of Cambridge published their work, in the October 2014 edition of the European Journal of Cancer Care, on the variation in experience among patients with different cancers and characteristics as an important step for assisting the design of targeted improvement interventions.
Analysis of 2011/2012 CPES (n = 69 086) data showed that younger and very old, ethnic minority patients and women consistently reported worse experiences across their responses to the questions. Beyond socio-demographic variation, patients with small intestine/rarer lower gastrointestinal, multiple myeloma and hepatobiliary cancers were most likely to report negative experiences whereas patients with breast, melanoma and testicular cancer were least likely.
There were also inequalities in experience among patients with cancers treated by the same specialty. Specifically, patients with ovarian, multiple myeloma, anal, hepatobiliary and renal cancer reported notably worse experiences than patients with other gynaecological, haematological, gastrointestinal and urological malignancies respectively.